{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T19:49:11Z","timestamp":1785440951975,"version":"3.56.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,11,23]],"date-time":"2021-11-23T00:00:00Z","timestamp":1637625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,23]],"date-time":"2021-11-23T00:00:00Z","timestamp":1637625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"the science and technology program of guangzhou .","award":["201604020094"],"award-info":[{"award-number":["201604020094"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Imaging Biol"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s11307-021-01679-w","type":"journal-article","created":{"date-parts":[[2021,11,23]],"date-time":"2021-11-23T18:02:58Z","timestamp":1637690578000},"page":"309-320","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Clinical Utility of F-18 Labeled Fibroblast Activation Protein Inhibitor (FAPI) for Primary Staging in Lung Adenocarcinoma: a Prospective Study"],"prefix":"10.1007","volume":"24","author":[{"given":"Youcai","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinqing","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penghao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengzhi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1997-5687","authenticated-orcid":false,"given":"Xinlu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,23]]},"reference":[{"key":"1679_CR1","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.radonc.2015.02.015","volume":"114","author":"TP Coroller","year":"2015","unstructured":"Coroller TP, Grossmann P, Hou Y et al (2015) CT-based radiomic signature predicts distant metastasis in lung adenocarcinoma. Radiother Oncol 114:345\u2013350","journal-title":"Radiother Oncol"},{"key":"1679_CR2","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41419-017-0063-y","volume":"9","author":"TV Denisenko","year":"2018","unstructured":"Denisenko TV, Budkevich IN, Zhivotovsky B (2018) Cell death-based treatment of lung adenocarcinoma. Cell Death Dis 9:117","journal-title":"Cell Death Dis"},{"key":"1679_CR3","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s11912-011-0203-y","volume":"14","author":"L Nayak","year":"2012","unstructured":"Nayak L, Lee EQ, Wen PY (2012) Epidemiology of brain metastases. Curr Oncol Rep 14:48\u201354","journal-title":"Curr Oncol Rep"},{"key":"1679_CR4","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1200\/JCO.2004.12.149","volume":"22","author":"JS Barnholtz-Sloan","year":"2004","unstructured":"Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE (2004) Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 22:2865\u20132872","journal-title":"J Clin Oncol"},{"key":"1679_CR5","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s00259-018-4109-x","volume":"46","author":"J Kirchner","year":"2019","unstructured":"Kirchner J, Sawicki LM, Nensa F et al (2019) Prospective comparison of (18)F-FDG PET\/MRI and (18)F-FDG PET\/CT for thoracic staging of non-small cell lung cancer. Eur J Nucl Med Mol Imaging 46:437\u2013445","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1679_CR6","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1148\/radiol.2292021598","volume":"229","author":"G Antoch","year":"2003","unstructured":"Antoch G, Stattaus J, Nemat AT et al (2003) Non-small cell lung cancer: dual-modality PET\/CT in preoperative staging. Radiology 229:526\u2013533","journal-title":"Radiology"},{"key":"1679_CR7","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1007\/s00259-019-04346-z","volume":"46","author":"FL Giesel","year":"2019","unstructured":"Giesel FL, Heussel CP, Lindner T et al (2019) FAPI-PET\/CT improves staging in a lung cancer patient with cerebral metastasis. Eur J Nucl Med Mol Imaging 46:1754\u20131755","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1679_CR8","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1007\/s00259-020-04769-z","volume":"47","author":"H Chen","year":"2020","unstructured":"Chen H, Pang Y, Wu J et al (2020) Comparison of [(68)Ga]Ga-DOTA-FAPI-04 and [(18)F] FDG PET\/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer. Eur J Nucl Med Mol Imaging 47:1820\u20131832","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1679_CR9","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1023\/A:1006308808769","volume":"44","author":"PD Schellinger","year":"1999","unstructured":"Schellinger PD, Meinck HM, Thron A (1999) Diagnostic accuracy of MRI compared to CCT in patients with brain metastases. J Neurooncol 44:275\u2013281","journal-title":"J Neurooncol"},{"key":"1679_CR10","doi-asserted-by":"publisher","first-page":"801","DOI":"10.2967\/jnumed.119.227967","volume":"60","author":"C Kratochwil","year":"2019","unstructured":"Kratochwil C, Flechsig P, Lindner T et al (2019) (68)Ga-FAPI PET\/CT: Tracer Uptake in 28 Different Kinds of Cancer. J Nucl Med 60:801\u2013805","journal-title":"J Nucl Med"},{"key":"1679_CR11","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.apradiso.2012.06.034","volume":"76","author":"A Sanchez-Crespo","year":"2013","unstructured":"Sanchez-Crespo A (2013) Comparison of Gallium-68 and Fluorine-18 imaging characteristics in positron emission tomography. Appl Radiat Isot 76:55\u201362","journal-title":"Appl Radiat Isot"},{"key":"1679_CR12","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2967\/jnumed.120.245084","volume":"62","author":"FL Giesel","year":"2021","unstructured":"Giesel FL, Adeberg S, Syed M et al (2021) FAPI-74 PET\/CT Using Either (18)F-AlF or Cold-Kit (68)Ga Labeling: Biodistribution, Radiation Dosimetry, and Tumor Delineation in Lung Cancer Patients. J Nucl Med 62:201\u2013207","journal-title":"J Nucl Med"},{"key":"1679_CR13","doi-asserted-by":"crossref","unstructured":"Wang S, Zhou X, Xu X, et al. (2021) Clinical translational evaluation of Al(18)F-NOTA-FAPI for fibroblast activation protein-targeted tumour imaging. European journal of nuclear medicine and molecular imaging.","DOI":"10.21203\/rs.3.rs-231262\/v1"},{"key":"1679_CR14","doi-asserted-by":"publisher","first-page":"649148","DOI":"10.3389\/fonc.2021.649148","volume":"11","author":"X Jiang","year":"2021","unstructured":"Jiang X, Wang X, Shen T et al (2021) FAPI-04 PET\/CT Using [(18)F]AlF Labeling Strategy: Automatic Synthesis, Quality Control, and In Vivo Assessment in Patient. Front Oncol 11:649148","journal-title":"Front Oncol"},{"key":"1679_CR15","unstructured":"Haberkorn, Uwe, Loktev, et al. FAP INHIBITOR."},{"key":"1679_CR16","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1148\/radiol.2020203275","volume":"298","author":"Y Pang","year":"2021","unstructured":"Pang Y, Zhao L, Luo Z et al (2021) Comparison of (68)Ga-FAPI and (18)F-FDG Uptake in Gastric, Duodenal, and Colorectal Cancers. Radiology 298:393\u2013402","journal-title":"Radiology"},{"key":"1679_CR17","doi-asserted-by":"crossref","unstructured":"Li Y, Zhang Y, Fang Q, et al. (2021) Radiomics analysis of [(18)F]FDG PET\/CT for microvascular invasion and prognosis prediction in very-early- and early-stage hepatocellular carcinoma. European journal of nuclear medicine and molecular imaging.","DOI":"10.1007\/s00259-020-05119-9"},{"key":"1679_CR18","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1007\/s00259-019-04444-y","volume":"46","author":"M Rohrich","year":"2019","unstructured":"Rohrich M, Loktev A, Wefers AK et al (2019) IDH-wildtype glioblastomas and grade III\/IV IDH-mutant gliomas show elevated tracer uptake in fibroblast activation protein-specific PET\/CT. Eur J Nucl Med Mol Imaging 46:2569\u20132580","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1679_CR19","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s00259-018-4210-1","volume":"46","author":"KC Ho","year":"2019","unstructured":"Ho KC, Toh CH, Li SH et al (2019) Prognostic impact of combining whole-body PET\/CT and brain PET\/MR in patients with lung adenocarcinoma and brain metastases. Eur J Nucl Med Mol Imaging 46:467\u2013477","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1679_CR20","unstructured":"Pang Y, Zhao L, Luo Z, et al. (2020) Comparison of (68)Ga-FAPI and (18)F-FDG Uptake in Gastric, Duodenal, and Colorectal Cancers. Radiology 203275."},{"key":"1679_CR21","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1007\/s00259-020-05070-9","volume":"48","author":"X Shi","year":"2021","unstructured":"Shi X, Xing H, Yang X et al (2021) Comparison of PET imaging of activated fibroblasts and (18)F-FDG for diagnosis of primary hepatic tumours: a prospective pilot study. Eur J Nucl Med Mol Imaging 48:1593\u20131603","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1679_CR22","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1007\/s00259-008-0847-5","volume":"35","author":"T Hatakeyama","year":"2008","unstructured":"Hatakeyama T, Kawai N, Nishiyama Y et al (2008) 11C-methionine (MET) and 18F-fluorothymidine (FLT) PET in patients with newly diagnosed glioma. Eur J Nucl Med Mol Imaging 35:2009\u20132017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1679_CR23","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s00259-012-2295-5","volume":"40","author":"AW Glaudemans","year":"2013","unstructured":"Glaudemans AW, Enting RH, Heesters MA et al (2013) Value of 11C-methionine PET in imaging brain tumours and metastases. Eur J Nucl Med Mol Imaging 40:615\u2013635","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1679_CR24","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1007\/s00259-018-4207-9","volume":"46","author":"I Law","year":"2019","unstructured":"Law I, Albert NL, Arbizu J et al (2019) Joint EANM\/EANO\/RANO practice guidelines\/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [(18)F]FDG: version 1.0. Eur J Nucl Med Mol Imaging 46:540\u2013557","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1679_CR25","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1148\/rg.2018180060","volume":"38","author":"A Kandathil","year":"2018","unstructured":"Kandathil A, Kay FU, Butt YM, Wachsmann JW, Subramaniam RM (2018) Role of FDG PET\/CT in the Eighth Edition of TNM Staging of Non-Small Cell Lung Cancer. Radiographics 38:2134\u20132149","journal-title":"Radiographics"},{"key":"1679_CR26","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","volume":"11","author":"P Goldstraw","year":"2016","unstructured":"Goldstraw P, Chansky K, Crowley J et al (2016) The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol 11:39\u201351","journal-title":"J Thorac Oncol"},{"key":"1679_CR27","doi-asserted-by":"publisher","first-page":"504","DOI":"10.6004\/jnccn.2017.0050","volume":"15","author":"DS Ettinger","year":"2017","unstructured":"Ettinger DS, Wood DE, Aisner DL et al (2017) Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 15:504\u2013535","journal-title":"J Natl Compr Canc Netw"},{"key":"1679_CR28","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s10585-017-9864-8","volume":"34","author":"AK Ciminera","year":"2017","unstructured":"Ciminera AK, Jandial R, Termini J (2017) Metabolic advantages and vulnerabilities in brain metastases. Clin Exp Metas 34:401\u2013410","journal-title":"Clin Exp Metas"},{"key":"1679_CR29","doi-asserted-by":"publisher","first-page":"e300","DOI":"10.3747\/co.20.1481","volume":"20","author":"A Ali","year":"2013","unstructured":"Ali A, Goffin JR, Arnold A, Ellis PM (2013) Survival of patients with non-small-cell lung cancer after a diagnosis of brain metastases. Curr Oncol 20:e300-306","journal-title":"Curr Oncol"},{"key":"1679_CR30","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/S1470-2045(20)30207-2","volume":"21","author":"F Barlesi","year":"2020","unstructured":"Barlesi F, Tomasini P (2020) Non-small-cell lung cancer brain metastases and PD-(L)1 immune checkpoint inhibitors. Lancet Oncol 21:607\u2013608","journal-title":"Lancet Oncol"},{"key":"1679_CR31","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1093\/neuonc\/nou099","volume":"17","author":"JL Villano","year":"2015","unstructured":"Villano JL, Durbin EB, Normandeau C, Thakkar JP, Moirangthem V, Davis FG (2015) Incidence of brain metastasis at initial presentation of lung cancer. Neuro Oncol 17:122\u2013128","journal-title":"Neuro Oncol"},{"key":"1679_CR32","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/nrc882","volume":"2","author":"SS Gambhir","year":"2002","unstructured":"Gambhir SS (2002) Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2:683\u2013693","journal-title":"Nat Rev Cancer"},{"key":"1679_CR33","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1002\/cncr.30000","volume":"122","author":"PH Goncalves","year":"2016","unstructured":"Goncalves PH, Peterson SL, Vigneau FD et al (2016) Risk of brain metastases in patients with nonmetastatic lung cancer: Analysis of the Metropolitan Detroit Surveillance, Epidemiology, and End Results (SEER) data. Cancer 122:1921\u20131927","journal-title":"Cancer"},{"key":"1679_CR34","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1053\/j.semnuclmed.2015.03.004","volume":"45","author":"P Flechsig","year":"2015","unstructured":"Flechsig P, Mehndiratta A, Haberkorn U, Kratochwil C, Giesel FL (2015) PET\/MRI and PET\/CT in Lung Lesions and Thoracic Malignancies. Semin Nucl Med 45:268\u2013281","journal-title":"Semin Nucl Med"},{"key":"1679_CR35","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1097\/RLU.0000000000003357","volume":"46","author":"W Fu","year":"2021","unstructured":"Fu W, Liu L, Liu H, Zhou Z, Chen Y (2021) Increased FAPI Uptake in Brain Metastasis From Lung Cancer on 68Ga-FAPI PET\/CT. Clin Nucl Med 46:e1\u2013e2","journal-title":"Clin Nucl Med"},{"key":"1679_CR36","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1097\/RLU.0000000000003231","volume":"45","author":"B Hao","year":"2020","unstructured":"Hao B, Wu J, Pang Y, Sun L, Chen H (2020) 68Ga-FAPI PET\/CT in Assessment of Leptomeningeal Metastases in a Patient With Lung Adenocarcinoma. Clin Nucl Med 45:784\u2013786","journal-title":"Clin Nucl Med"},{"key":"1679_CR37","doi-asserted-by":"publisher","first-page":"W215","DOI":"10.2214\/AJR.13.10572","volume":"201","author":"M Kruse","year":"2013","unstructured":"Kruse M, Sherry SJ, Paidpally V, Mercier G, Subramaniam RM (2013) FDG PET\/CT in the management of primary pleural tumors and pleural metastases. AJR Am J Roentgenol 201:W215-226","journal-title":"AJR Am J Roentgenol"}],"container-title":["Molecular Imaging and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-021-01679-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11307-021-01679-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-021-01679-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T15:24:59Z","timestamp":1649172299000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11307-021-01679-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,23]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["1679"],"URL":"https:\/\/doi.org\/10.1007\/s11307-021-01679-w","relation":{},"ISSN":["1536-1632","1860-2002"],"issn-type":[{"value":"1536-1632","type":"print"},{"value":"1860-2002","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,23]]},"assertion":[{"value":"12 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the Clinical Research Ethics Committee of the First Affiliated Hospital of Guangzhou Medical University and the Chinese Clinical Trial Registry (ChiCTR2100044944) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}